Silence Therapeutics plc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
United Kingdom
Country
United Kingdom
Business Address
12 HAMMERSMITH GROVE, LONDON, , W6 7AP
Mailing Address
12 HAMMERSMITH GROVE, LONDON, , W6 7AP
Phone
44-0-20-3457 6900
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 8-K/A Current report amendment | December 22, 2025 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Advanced lead candidate SLN360 into Phase 3 clinical trials for high Lp(a).
- Reported positive Phase 2 data for SLN124, with a pivotal study planned for 2026.
Material Events
8-K
Leadership Change
December 15, 2025
High Impact
- Silence Therapeutics plc's President and CEO, Craig Tooman, has departed by mutual agreement and stepped down from the Board of Directors.
- Iain Ross, the current Chairman of the Board, has been appointed as interim CEO.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.